DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Information source: INSYS Therapeutics Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mucositis; Pain; Unspecified Adult Solid Tumor, Protocol Specific

Intervention: Fentanyl sublingual spray (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: INSYS Therapeutics Inc

Official(s) and/or principal investigator(s):
Lisa J. Stearns, MD, Principal Investigator, Affiliation: Center for Pain and Supportive Care, PLLC


This was an open-label, single-dose study to assess the safety, tolerability, and absorption/distribution kinetics of a single 100 g dose of fentanyl sublingual spray in opioid-tolerant cancer subjects, with or without oral mucositis.

Clinical Details

Official title: Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis

Study design: Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: Cmax of Fentanyl

Secondary outcome:

Tmax of Fentanyl

AUC0-last of Fentanyl

Detailed description: RATIONALE: One dose of fentanyl sublingual spray may be effective in relieving pain in opioid-tolerant cancer patients. PURPOSE: This phase III trial is studying the side effects of fentanyl sublingual spray and to see how well it works in treating opioid-tolerant cancer patients with or without oral mucositis. OBJECTIVES: Primary

- To compare the absorption/distribution kinetics of a single dose of fentanyl sublingual

spray in opioid-tolerant cancer patients with or without oral mucositis.

- To evaluate the safety and tolerability of this regimen.

OUTLINE: This is a multicenter study. Patients fast for at least 8 hours before and at least 4 hours after and no water is allowed for at least 1 hour before and at least 1 hour after study drug administration. Patients receive a single dose of fentanyl sublingual spray while in an upright position in clinical care recliners or beds, and remain in an upright posture for at least 4 hours after administration. Patients are instructed not to swallow for at least 5 minutes after administration and not to expectorate the drug. After study drug administration, 10 blood samples are collected over a 12-hour period for pharmacokinetic and other analyses.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.



- Diagnosis of cancer and meets 1 of the following criteria:

- Mild mucositis, defined as grade 1 (erythema of the mucosa) or 2 (patchy

ulcerations or pseudomembranes) on the day of study drug administration.

- No mucositis, defined as normal oral cavity upon examination on the day of study

drug administration.

- Opioid-tolerant, defined as patients who are taking ≥ 60 mg of oral morphine/day, ≥

30 mg of oxycodone/day, ≥ 8 mg of oral hydromorphone/day, or an equianalgesic dose of another opioid for ≥ 7 days for cancer-related pain.

- Persistent pain related to cancer or its treatment over the past 7 days.

- No brain metastases with signs or symptoms of increased intracranial pressure.


- Negative pregnancy test.

- Agree to be confined to study site for approximately 12 hours, to eat only the food

served by the study unit during the study confinement period, and to consume all food provided at the designated meal or snack times.

- No history of major organ system impairment or disease that, in the investigator's or

his/her designee's opinion, could increase the risk associated with the use of opioids.

- No uncontrolled hypertension despite antihypertensive therapy or history of

hypertensive crisis within the past 2 years.

- No recent history (within the past 2 years) of transient ischemic attacks, neural

vascular disease, stroke, or cerebral aneurysms.

- No intolerable side effects to opioids or fentanyl.


- See Disease Characteristics.

- More than 30 days since prior investigational agents.

- More than 14 days since prior monoamine oxidase inhibitors.

- No prior participation in either Insys Fentanyl Sublingual Spray Phase III study

INSYS-INS-05-001 or INSYS-INS-06-007.

- No other concurrent use of any fentanyl product.

- Patients who have received Actiq®, Fentora®, or Duragesic® are eligible after a

7-day washout.

- No concurrent medications (prescription, over-the-counter, vitamin, or herbal

substances) except for hormonal contraceptives and/or ≤ 3 doses of acetaminophen at ≤ 1 g each.

Locations and Contacts

InSys Therapeutics, Incorporated, Scottsdale, Arizona 85258, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: October 2009
Last updated: June 25, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017